Acute Respiratory Infections (ARIs)
Conditions
Keywords
Point of care diagnostics, CRP (C- Reactive Protein), MxA (Myxovirus resistance protein A)
Brief summary
The goal of this observational study is to learn about the performance and ease of use of FebriDx when operated by persons without laboratory experience or training in patients with acute respiratory symptoms. The main question it aims to answer is: • Is FebriDx accurate at differentiating bacterial from non-bacterial respiratory infections when used by untrained operators? Trained and untrained participants will run the FebriDx test on patients with respiratory symptoms to evaluate comparability.
Detailed description
A prospective, multi-center, blinded observational study to demonstrate that the FebriDx test meets the CLIA statutory criteria for waiver by providing sufficient assurance that the addition of a new operator population (untrained) and environment of use (waived) will not adversely impact the performance or safety of the test. The study aims to: * Demonstrate that FebriDx® Test is accurate and the operator can perform the test with a negligible risk of erroneous result. * As a secondary objective, ease-of-use objective data and subjective feedback relating to the device and its operator interface will be collected at the end of the study and assessed for comparability.
Interventions
DIAGNOSTIC_TESTRapid point of care test to detect host immune response in ARI
FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
Sponsors
Biomedical Advanced Research and Development Authority
Lumos Diagnostics
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Subject exhibits or reports a new onset measured temperature (oral or tympanic) of greater than or equal to 100.5°F/38°C within 3 days (72 hours) of enrollment or at the visit * Subject has clinical suspicion for Acute Respiratory Infection and presents with at least one (1) of the following new onset symptoms beginning ≤ 7 days of enrollment: runny nose, nasal congestion, sore throat, cough, hoarse voice or shortness of breath
Exclusion criteria
* Subject is unable or unwilling to provide signed, Informed Consent * Subject is less than 12 years old or over 64 years old * Subject has a fever that started more than 3 days (\> 72 hours) prior to enrollment * Subject has symptoms of Acute Respiratory Infection that started \> 7 days of enrollment * Subject is receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in the last 30 days * Subject is in an immunocompromised state (e.g. HIV) or taking immunosuppressive or chemotherapeutic medications in the last 30 days (e.g. oral steroids, Methotrexate, Cyclosporine, Antimetabolite chemotherapy, interferon therapy) * Subject has taken antibiotics or antiviral therapy in the last 14 days * Subject received a live viral immunization in the last 14 days * Subject has significant trauma or burns (\> 5% total body surface area or full thickness (3rd°)) in the last 30 days * Subject has had major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the last 30 days * Subject has a history of a myocardial infarction or stroke in the last 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance | Day 1 | Positive Percent Agreement (PPA), Negative Percent Agreement (NPA) and 95% confidence intervals will be calculated for each untrained operator and compared to performance in trained operators (truth). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Usability | Day 1 | Ease-of-use objective data and subjective feedback relating to the device and its Operator interface will be collected at the end of the study |
Countries
United States
Outcome results
None listed